| Name | Title | Contact Details |
|---|
Diamond Baseball Holdings (DBH) is a New York-based company founded in 2021 that owns and operates a significant portfolio of Minor League Baseball (MiLB) clubs affiliated with Major League Baseball. The company focuses on professional management, best practices, and innovative investments to enhance fan experiences, brand engagement, player conditions, and community impact. As of 2024, DBH has acquired 33 teams, making it one of the largest ownership groups in MiLB history. The company emphasizes maintaining baseballs traditions while upgrading facilities and improving player welfare. DBH operates as part of Silver Lakes sports investments and applies private equity strategies to enhance operations and achieve market-beating returns. Its initiatives include partnerships for stadium upgrades and innovations aimed at boosting fan attendance and creating superior environments for both fans and players.
Arch Insurance Group Inc., a division of Arch Capital Group Ltd. (ACGL), is a market-leading specialty insurer. We provide a wide range of property, casualty and specialty insurance for corporations, professional firms and financial institutions across the United States and Canada. Our insurance group in North America consists of Arch Insurance Company, Arch Specialty Insurance Company and Arch Excess & Surplus Insurance Company. Arch Insurance Groups executive offices are located at One Liberty Plaza in New York City, with regional offices located in New York City (Northeast Region), Atlanta (Southeast Region), Chicago (Central Region) and San Francisco (Western Region), as well as other offices throughout the U.S. to support our business. Arch Insurance Company also operates a branch office in Toronto, Canada. ACGL is a Bermuda public limited liability company that provides insurance, reinsurance and mortgage insurance on a worldwide basis through operations in Bermuda, the United States, Canada, Europe, Australia and Hong Kong.
Farmers Union Insurance is committed to building stronger communities through the development and training of agents and employees, so as to deliver quality products and services at a profit level adequate to maintain a solid financial base. * Not all products listed are underwritten by Farmers Union Insurance
Richelieu is Canadas leading distributor, importer, and manufacturer of specialty hardware and complementary products - and also ranks among the top players in its specialty in North America. We are the leading driver of worldwide innovations in functional and decorative hardware. We provide manufacturers and retailers with a UNIQUE mix of more than 130,000 different items in a host of categories: decorative hardware · kitchen accessories · lighting systems · functional and decorative mouldings · functional hardware · ergonomic workstations · finishing and decorating products · high-pressure laminates · veneer sheets and edgebanding products · screws and fasteners... We take pride in serving more than 110,000 customers across North America, in two major markets: * Manufacturers o Kitchen and bathroom cabinet manufacturers o Home and office furniture manufacturers o Residential and commercial woodworking industry, etc. * Retailers o Purchasing groups o Small and medium-sized hardware stores o Renovation superstores 113 distribution centers in North America. Some 3,000 people work throughout the network, more than half are specialized in sales and marketing, so as to provide our extensive base of loyal customers with first-class service. Richelieu Hardware Ltd. is a public company listed on the Toronto Stock Exchange (TSX) under the ticker symbol RCH.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.